Donald Trump's statement about alleged "reverse surgeries" ordered at hospitals contrasts with funding policies, legal agreements, clinical evidence, and injunctions issued by federal judges.
Donald Trump stated at a campaign rally in Myrtle Beach, South Carolina, that hospitals in the United States have begun performing "reverse surgeries" on transgender individuals at his instruction. The statement, presented to his supporters as a direct result of his policy, provoked immediate backlash as it does not align with the description of federal orders, legal agreements, or the clinical practices cited by specialists.
Trump said, "In fact, hospitals are now doing reverse surgeries at my order" and added, "They are doing reverse surgeries. No one knew until now." However, the information available in the news does not identify a presidential mandate requiring doctors or hospitals to surgically reverse a transition, so the claim must be distinguished from the financial and regulatory measures that have indeed driven institutional changes.
Adrian Shanker, a former senior health policy advisor in the Biden administration, rejected the notion that personal medical decisions should be subordinated to a president's preferences. "Trans people deserve access to the care their bodies need, not the care that President Trump thinks they need," Shanker stated, questioning the intervention of partisan politics in the relationship between patients and professionals.
Dr. Demetre Daskalakis, medical director of Callen-Lorde, also expressed doubts about the presidential version and noted that he was not aware of any non-clinicians ordering such hospital procedures. His comment points to a central difference: a political statement may describe an intention or a rhetorical victory, but it does not replace a clinical order issued by the teams responsible for care.
In political language, the term "reverse surgeries" may suggest that hospitals received instructions to undo previous procedures on a widespread basis. The news, on the other hand, describes policies aimed at modifying access through grants, public coverage, and agreements with institutions, mechanisms capable of altering hospital decisions without directly ordering a specific operation.
The controversy also reveals the importance of verifying what exactly "at my order" means when a leader speaks about health. In this case, the cited experts and the mentioned legal records present a landscape of financial pressure and litigation, not evidence of a presidential chain of command instructing surgeons on which procedures to perform.
An executive order signed in January 2025 instructed federal agencies to restrict research and education grants for health systems that provided gender-affirming care to individuals under 19 years old. This measure did not order reversal surgeries but used access to public resources as a tool to influence institutions offering certain treatments.
The information also indicates that the Centers for Medicare and Medicaid completed a rule in August 2026 aimed at ending Medicaid funding for gender-affirming treatments for minors. The provision included a three-month hormonal reduction period, but its described effect was budgetary and coverage-related, not an instruction for hospitals to operate on patients with the aim of reversing their transition.
This type of pressure can have significant consequences even when the government does not issue an individual medical order. Hospitals rely on grants, educational programs, and public reimbursements, so the threat of losing funding can lead their administrators to pause services, revise protocols, or limit available care for certain groups.
The difference between a clinical order and a financial condition is crucial for evaluating Trump's assertion. The described directives seek to withdraw resources or coverage from certain practices, while the decision regarding a specific procedure continues to depend on patients, specialists, institutional protocols, and professional standards, within the framework ultimately determined by the courts.
The Department of Justice has resorted to judicial agreements with large medical centers to establish commitments related to services intended for individuals wishing to reverse their transition. Among the mentioned institutions are Texas Children's Hospital and the Cleveland Clinic, although these civil agreements do not obligate every patient to undergo surgery nor do they turn a medical option into an automatic procedure.
According to available information, a June 2026 agreement committed the Cleveland Clinic to allocate USD $2,000,000 in services for individuals who had received care before the age of 19 and later decided to reverse their transition. The financial commitment can be politically presented as a consequence of the new guidelines, but it does not equate to ordering that all affected individuals receive surgical intervention.
The threat of losing millions of dollars in federal grants, however, did lead several institutions to pause treatments for youth. The information mentions NYU Langone, Denver Health, and Children's National Hospital among the centers that suspended or slowed services, an institutional reaction that helps explain why policy can change medical offerings without the need for a direct surgical order.
The agreements and hospital pauses are part of a broader dispute over the extent of federal power in gender-affirming care. For advocates of restrictions, conditioning public resources is a legitimate way to implement a policy; for critics, that strategy interferes with individualized decisions and creates uncertainty for patients, families, and professionals.
The described institutional movement seems plausibly related to the regulatory and budgetary pressure from the Trump administration. Available information attributes the pauses or closures of youth programs in centers like NYU Langone to that pressure, but does not identify a presidential order that directly imposed reversal surgeries.
Legally, the landscape remains open. The rule published in the Federal Register contemplates that state agencies may continue to claim funds for beneficiaries already receiving hormonal therapy, showing that the scope of the policy includes exceptions and does not equate to a general surgical order.
The news cites a 2024 study published in JAMA Network Open, which analyzed insurance claims corresponding to more than 23 million adults across the country. Researchers found zero gender-affirming surgeries in youths aged 12 or younger during 2019, a finding that contradicts any reading that presents such interventions as a widespread hospital practice among younger minors.
The study does not alone resolve all questions about gender care nor does it allow for the evaluation of each individual clinical decision. However, it does provide a benchmark for discussing the frequency of certain procedures and shows why general claims require documentary support, especially when they may guide public decisions affecting access to medical services.
Andrew Ortiz, senior policy attorney at the Transgender Legal Defense and Education Fund, stated that the administration's measures show where it wants to focus its attention. Health groups argue that individualized decisions should be based on clinical evidence and professional assessment, not on political pressure exerted through budgetary threats.
The judicial front has added another layer of uncertainty. Federal Judge Brendon Hurson issued a temporary order prohibiting federal agencies from withholding money from providers treating youths for their identity, while Federal Judge Lauren King in Washington blocked directives after 20 states argued they represented a serious institutional breach.
Alex Sheldon, executive director of GLMA, warned that forcing doctors to withhold care based on clinical criteria would damage the credibility of the medical system. Lawsuits continue to pit federal regulatory power against the role of states in health administration, so the practical scope of policies may change as judicial decisions progress.
The evidence described suggests that presidential rules have interrupted or limited some care through threats regarding budgets and coverage, but it does not show that a mandate compels professionals to perform "reverse surgeries." That distinction matters because a policy can produce concrete consequences in hospitals without thereby becoming a medical order for every patient.
It also matters to separate civil agreements from clinical instructions. That an institution allocates USD $2,000,000 to services for individuals wishing to reverse their transition does not mean that all patients must receive them, nor that doctors have to recommend a specific intervention; the agreement establishes an institutional commitment, while the individual decision depends on the corresponding assessment.
The situation remains open due to litigation over funding and temporary orders from federal judges. As those disputes continue, some hospitals have paused treatments for youths, and other providers face the possibility of losing resources, a tension that may alter the available care even before a definitive resolution exists.
Trump's statement summarizes a complex controversy in a blunt phrase, but the data, agreements, and cited rulings describe a much more indirect mechanism. The underlying debate is about determining how far political leaders can go in using federal funds to influence medical decisions that are normally made between patients and professionals.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.



























Bitcoin tore through the mid-$60,000s, cleared $70,000, blew past $75,000, and briefly touched $79,000+ before easing back to around $77,000 — a 20%+ move in a single week. The mood across crypto flipped almost overnight. But a violent rally is only the opening act. The more explosive the move, the more it calls for a clear, calm mind.


